Zotarolimus eluting stents showed more homogeneous neointimal coverage and better preserved endothelial function compared to paclitaxel eluting stents at 9 months post-implantation.
Observational (n=14)
Does zotarolimus-eluting stent improve re-endothelialization and endothelial function compared to paclitaxel-eluting stent in patients undergoing DES implantation?
Zotarolimus-eluting stents appear to better preserve endothelial function and promote more homogeneous neointimal coverage compared to paclitaxel-eluting stents at 9 months post-implantation.
BACKGROUND: Several studies have reported re-endothelialization and endothelial function after drug-eluting stent (DES) implantation; however, the relationship between re-endothelialization and endothelial function after DES implantation has not been investigated yet. METHODS: A total of 14 patients underwent evaluation of re-endothelialization by optical coherence tomography (OCT) and endothelial function by incremental Ach infusion at 9 months after DES implantation (ZES: N = 7, PES: N = 7). The neointimal thickness (NIT) inside each strut, strut coverage, and malapposition at every 1 mm cross-section were evaluated by OCT and the endothelial function was estimated by measuring the coronary vaso-reactivity in response to acetylcholine (Ach) infusion into coronary arteries. RESULTS: Zotarolims eluting stent (ZES), compared with paclitaxcel eluting stent (PES), showed more homogeneous neointimal coverage of stent struts and low rate of malapposition. Vasoconstriction in response to Ach in the peri-stent region was also less pronounced in ZES than PES. In particular, vasoconstriction was more often observed in cases with inhomogeneous neointimal coverage of stent struts in the PES group. CONCLUSIONS: Our findings suggest that endothelial function seems to be better preserved with ZES than PES, and homogeneous neointimal coverage of stent struts seem to be associated with the preserved endothelial function.
Murase et al. (Tue,) conducted a observational in Drug-eluting stent (DES) implantation (n=14). Zotarolimus eluting stent (ZES) vs. Paclitaxel eluting stent (PES) was evaluated on Re-endothelialization by OCT and endothelial function by incremental Ach infusion. Zotarolimus eluting stents showed more homogeneous neointimal coverage and better preserved endothelial function compared to paclitaxel eluting stents at 9 months post-implantation.